Review explains statistical pitfalls in anti-drug antibody assay cut points
Academic source · Bioanalysis / PubMed
Source published: · Event / reporting date: 2026-11-02
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What the paper reports
Based on the PubMed abstract, this review explains how sample selection, experimental balance, outlier handling, transformation, and statistical methods affect anti-drug antibody assay cut points. It addresses screening, confirmation, titers, drug tolerance, and reassessment using clinical baseline samples. This is a practical review of validation decisions, not a new clinical efficacy study.
Why this paper is included
Analysis: Bioanalytical teams may use the review to challenge cut-point assumptions and plan defensible immunogenicity workflows across assay development and clinical follow-up.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections